1
|
Cattaneo C, Cancelli V, Imberti L, Dobbs K, Sottini A, Pagani C, Belotti A, Re A, Anastasia A, Quaresima V, Tucci A, Chiorini JA, Su HC, Cohen JI, Burbelo PD, Rossi G, Notarangelo LD. Production and persistence of specific antibodies in COVID-19 patients with hematologic malignancies: role of rituximab. Blood Cancer J 2021; 11:151. [PMID: 34521813 PMCID: PMC8438656 DOI: 10.1038/s41408-021-00546-9] [Citation(s) in RCA: 27] [Impact Index Per Article: 9.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/11/2021] [Revised: 08/14/2021] [Accepted: 08/27/2021] [Indexed: 12/17/2022] Open
Abstract
The ability of patients with hematologic malignancies (HM) to develop an effective humoral immune response after COVID-19 is unknown. A prospective study was performed to monitor the immune response to SARS-CoV-2 of patients with follicular lymphoma (FL), diffuse large B-cell lymphoma (DLBCL), chronic lymphoproliferative disorders (CLD), multiple myeloma (MM), or myelodysplastic/myeloproliferative syndromes (MDS/MPN). Antibody (Ab) levels to the SARS-CoV-2 nucleocapsid (N) and spike (S) protein were measured at +1, +3, +6 months after nasal swabs became PCR-negative. Forty-five patients (9 FL, 8 DLBCL, 8 CLD, 10 MM, 10 MDS/MPS) and 18 controls were studied. Mean anti-N and anti-S-Ab levels were similar between HM patients and controls, and shared the same behavior, with anti-N Ab levels declining at +6 months and anti-S-Ab remaining stable. Seroconversion rates were lower in HM patients than in controls. In lymphoma patients mean Ab levels and seroconversion rates were lower than in other HM patients, primarily because all nine patients who had received rituximab within 6 months before COVID-19 failed to produce anti-N and anti-S-Ab. Only one patient requiring hematological treatment after COVID-19 lost seropositivity after 6 months. No reinfections were observed. These results may inform vaccination policies and clinical management of HM patients.
Collapse
Affiliation(s)
- C Cattaneo
- Hematology, ASST Spedali Civili, Brescia, Italy.
| | - V Cancelli
- Hematology, ASST Spedali Civili, Brescia, Italy
| | - L Imberti
- CREA (AIL Center for Hemato-Oncologic Research), Diagnostic Department, ASST Spedali Civili di Brescia, Brescia, Italy
| | - K Dobbs
- Laboratory of Clinical Immunology and Microbiology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA
| | - A Sottini
- CREA (AIL Center for Hemato-Oncologic Research), Diagnostic Department, ASST Spedali Civili di Brescia, Brescia, Italy
| | - C Pagani
- Hematology, ASST Spedali Civili, Brescia, Italy
| | - A Belotti
- Hematology, ASST Spedali Civili, Brescia, Italy
| | - A Re
- Hematology, ASST Spedali Civili, Brescia, Italy
| | - A Anastasia
- Hematology, ASST Spedali Civili, Brescia, Italy
| | - V Quaresima
- CREA (AIL Center for Hemato-Oncologic Research), Diagnostic Department, ASST Spedali Civili di Brescia, Brescia, Italy
| | - A Tucci
- Hematology, ASST Spedali Civili, Brescia, Italy
| | - J A Chiorini
- National Institute of Dental and Craniofacial Research, NIH, Bethesda, MD, USA
| | - H C Su
- Laboratory of Clinical Immunology and Microbiology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA
| | - J I Cohen
- Laboratory of Infectious Diseases, NIAID, NIH, Bethesda, MD, USA
| | - P D Burbelo
- National Institute of Dental and Craniofacial Research, NIH, Bethesda, MD, USA
| | - G Rossi
- Hematology, ASST Spedali Civili, Brescia, Italy
| | - L D Notarangelo
- Laboratory of Clinical Immunology and Microbiology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA
| |
Collapse
|
2
|
Cattaneo C, Cancelli V, Pagani C, Ogna A, Tucci A, Rossi G, Quaresima V, Sotttini A, Dobbs K, Notarangelo LD, Cohen JI, Burbelo PD. IMPAIRED HUMORAL RESPONSE IN LYMPHOMA PATIENTS SURVIVING THE ACUTE PHASE OF COVID‐19. Hematol Oncol 2021. [PMCID: PMC8427060 DOI: 10.1002/hon.196_2880] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Affiliation(s)
- C. Cattaneo
- ASST‐Spedali Civili Hematology Brescia Italy
| | - V. Cancelli
- ASST‐Spedali Civili Hematology Brescia Italy
| | - C. Pagani
- ASST‐Spedali Civili Hematology Brescia Italy
| | - A. Ogna
- ASST‐Spedali Civili Hematology Brescia Italy
| | - A. Tucci
- ASST‐Spedali Civili Hematology Brescia Italy
| | - G. Rossi
- ASST‐Spedali Civili Hematology Brescia Italy
| | - V. Quaresima
- CREA (Centro Ricerca AIL) ASST Spedali Civili di Brescia Diagnostic Department Brescia Italy
| | - A. Sotttini
- CREA (Centro Ricerca AIL) ASST Spedali Civili di Brescia Diagnostic Department Brescia Italy
| | - K. Dobbs
- National Institute of Allergy and Infectious Diseases National Institutes of Health Laboratory of Clinical Immunology and Microbiology Bethesda Maryland USA
| | - L. D. Notarangelo
- National Institute of Allergy and Infectious Diseases National Institutes of Health Laboratory of Clinical Immunology and Microbiology Bethesda Maryland USA
| | - J. I. Cohen
- National Institute of Allergy and Infectious Diseases National Institutes of Health Laboratory of Infectious Diseases Bethesda Maryland USA
| | - P. D. Burbelo
- National Institutes of Health National Institute of Dental and Craniofacial Research Bethesda Maryland USA
| |
Collapse
|
3
|
Giorgi-Pierfranceschi M, Paoletti O, Pan A, De Gennaro F, Nardecchia AL, Morandini R, Dellanoce C, Lombi S, Tala M, Cancelli V, Zambelli S, Bosio G, Romanini L, Testa S. Prevalence of asymptomatic deep vein thrombosis in patients hospitalized with SARS-CoV-2 pneumonia: a cross-sectional study. Intern Emerg Med 2020; 15:1425-1433. [PMID: 32840805 PMCID: PMC7445816 DOI: 10.1007/s11739-020-02472-3] [Citation(s) in RCA: 24] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/16/2020] [Accepted: 08/05/2020] [Indexed: 12/13/2022]
Abstract
The association between coronavirus disease 2019 (COVID-19) pneumonia and venous thrombotic disorders is still unclear. We assessed the association between COVID-19 infection-related pneumonia and proximal deep-vein thrombosis (DVT) in a cohort of patients admitted to our hospital during the European outbreak in the front line of Cremona, Lombardy. In a single-center cross-sectional study, all patients hospitalized for more than 5 days in Internal Medicine Department with confirmed COVID-19 pneumonia received 2-point compressive ultrasound assessment (CUS) of the leg vein system during a single day. Ninety-four percent of patients received enoxaparin as standard pharmacological prophylaxis for venous thromboembolism. The presence of DVT was defined as incompressibility of popliteal or common femoral vein. Out of 121 patients with COVID-19 pneumonia (mean age 71.8, 66.3% males) hospitalized on March 31st, 70 stayed in hospital for over 5 days and 66 of them underwent CUS of deep venous system of the legs. The presence of asymptomatic DVT was found in 9 patients (13.6%). No symptomatic DVT was found. Patients with DVT showed mean age = 75.7 years, mean D-dimer levels = 4.02 ng/ml and all of them received enoxaparin for thromboprophylaxis, except one. Computed tomography pulmonary angiogram confirmed pulmonary embolism in five patients. One every seven patients with COVID-19-related pneumonia, hospitalized for more than 5 days, had asymptomatic proximal DVT and half of them had confirmed PE despite standard pharmacological thromboprophylaxis. This observational study suggests the need of an active surveillance through CUS in patients hospitalized with acute SARS-COV-2 and underline the need of a more intense thromboprophylaxis.
Collapse
Affiliation(s)
| | - Oriana Paoletti
- Haemostasis and Thrombosis Center, Hospital of Cremona, Cremona, Italy
| | - Angelo Pan
- Department of Infectious Disease, Hospital of Cremona, Cremona, Italy
| | - Fabio De Gennaro
- Department of Internal Medicine, Hospital of Cremona, Viale Concordia 1, 26100, Cremona, Italy
| | - Anna Laura Nardecchia
- Department of Internal Medicine, Hospital of Cremona, Viale Concordia 1, 26100, Cremona, Italy
| | | | - Claudia Dellanoce
- Haemostasis and Thrombosis Center, Hospital of Cremona, Cremona, Italy
| | - Samuele Lombi
- Department of Internal Medicine, Hospital of Cremona, Viale Concordia 1, 26100, Cremona, Italy
| | - Maurizio Tala
- Haemostasis and Thrombosis Center, Hospital of Cremona, Cremona, Italy
| | - Vanessa Cancelli
- Haemostasis and Thrombosis Center, Hospital of Cremona, Cremona, Italy
| | - Silvia Zambelli
- Haemostasis and Thrombosis Center, Hospital of Cremona, Cremona, Italy
| | - Giancarlo Bosio
- Department of Pneumology, Hospital of Cremona, Cremona, Italy
| | - Laura Romanini
- Department of Radiology, Hospital of Cremona, Cremona, Italy
| | - Sophie Testa
- Haemostasis and Thrombosis Center, Hospital of Cremona, Cremona, Italy
| |
Collapse
|
4
|
Bonetti G, Cancelli V, Coccoli G, Piccinelli G, Brugnoni D, Caimi L, Carta M. Which sample tube should be used for routine glucose determination? Prim Care Diabetes 2016; 10:227-232. [PMID: 26657574 DOI: 10.1016/j.pcd.2015.11.003] [Citation(s) in RCA: 20] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/25/2015] [Revised: 11/02/2015] [Accepted: 11/05/2015] [Indexed: 11/16/2022]
Abstract
BACKGROUND Glucose is one of the most frequently requested analytes in clinical laboratory. Blood glucose analysis is affected from in vitro glycolysis. In order to determine the most suitable blood collection tube for this purpose we have compared different tubes: sodium fluoride, lithium heparin, sodium fluoride/citrate buffer containing tubes and serum with clot activator tube for the measurement of glucose when the tube has been kept at room temperature (RT) for up to 4h. METHODS Venous blood was collected from 49 healthy volunteers into Sarstedt S-Monovettes for glucose analysis. Reference plasma glucose was determined in a lithium heparin tube and immediately placed in an ice/water slurry. Within 10min it was centrifuged at 4°C and plasma was separated from the blood cells. Samples have been preserved at RT for 1, 2 and 4h after drawing. Glucose has been determined using a hexokinase method. RESULTS Glucose levels tested in a serum with clot activator tube, in lithium heparin and in sodium fluoride/sodium EDTA tubes when compared with lithium-heparin reference plasma did not meet the desirable bias for glucose (±1.8%) when kept at RT for up to 4h. GlucoEXACT tubes, when corrected by the Sarsted recommended factor of 1.16, showed a mean (95% CI) bias of +0.96% (0.45-1.47) at 1h, +1.40% (0.88-1.93) at 2h and +0.95% (0.44-1.46) at 4h, reaching the analytical goal for the desirable bias. CONCLUSIONS Samples collected into GlucoEXACT tubes containing sodium fluoride/citrate buffer liquid mixture are equivalent to those collected in reference plasma tubes avoiding glycolysis completely and within a 4h delay in plasma separation.
Collapse
Affiliation(s)
| | - Vanessa Cancelli
- Clinical Chemistry Laboratory, A.O. Spedali Civili, Brescia, Italy
| | - Giulio Coccoli
- Clinical Chemistry Laboratory, A.O. Spedali Civili, Brescia, Italy
| | | | - Duilio Brugnoni
- Clinical Chemistry Laboratory, A.O. Spedali Civili, Brescia, Italy
| | - Luigi Caimi
- Clinical Chemistry Laboratory, A.O. Spedali Civili, Brescia, Italy; Department of Molecular and Translational Medicine, University of Brescia, Brescia, Italy
| | - Mariarosa Carta
- Clinical Chemistry and Haematology Laboratory, San Bortolo Hospital, Vicenza, Italy
| |
Collapse
|
5
|
Russo D, Malagola M, Skert C, Cancelli V, Turri D, Pregno P, Bergamaschi M, Fogli M, Testoni N, De Vivo A, Castagnetti F, Pungolino E, Stagno F, Breccia M, Martino B, Intermesoli T, Cambrin GR, Nicolini G, Abruzzese E, Tiribelli M, Bigazzi C, Usala E, Russo S, Russo-Rossi A, Lunghi M, Bocchia M, D'Emilio A, Santini V, Girasoli M, Lorenzo RD, Bernardi S, Palma AD, Cesana BM, Soverini S, Martinelli G, Rosti G, Baccarani M. Managing chronic myeloid leukaemia in the elderly with intermittent imatinib treatment. Blood Cancer J 2015; 5:e347. [PMID: 26383820 PMCID: PMC4648524 DOI: 10.1038/bcj.2015.75] [Citation(s) in RCA: 20] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/14/2015] [Accepted: 07/21/2015] [Indexed: 01/18/2023] Open
Abstract
The aim of this study was to investigate the effects of a non-standard, intermittent imatinib treatment in elderly patients with Philadelphia-positive chronic myeloid leukaemia and to answer the question on which dose should be used once a stable optimal response has been achieved. Seventy-six patients aged ⩾65 years in optimal and stable response with ⩾2 years of standard imatinib treatment were enrolled in a study testing a regimen of intermittent imatinib (INTERIM; 1-month on and 1-month off). With a minimum follow-up of 6 years, 16/76 patients (21%) have lost complete cytogenetic response (CCyR) and major molecular response (MMR), and 16 patients (21%) have lost MMR only. All these patients were given imatinib again, the same dose, on the standard schedule and achieved again CCyR and MMR or an even deeper molecular response. The probability of remaining on INTERIM at 6 years was 48% (95% confidence interval 35-59%). Nine patients died in remission. No progressions were recorded. Side effects of continuous treatment were reduced by 50%. In optimal and stable responders, a policy of intermittent imatinib treatment is feasible, is successful in about 50% of patients and is safe, as all the patients who relapsed could be brought back to optimal response.
Collapse
Affiliation(s)
- D Russo
- Unit of Blood Diseases and Stem Cell Transplantation, University of Brescia, Brescia, Italy
| | - M Malagola
- Unit of Blood Diseases and Stem Cell Transplantation, University of Brescia, Brescia, Italy
| | - C Skert
- Unit of Blood Diseases and Stem Cell Transplantation, University of Brescia, Brescia, Italy
| | - V Cancelli
- Unit of Blood Diseases and Stem Cell Transplantation, University of Brescia, Brescia, Italy
| | - D Turri
- Ematologia 1-TMO, AOR Villa Sofia-Cervello, Palermo, Italy
| | - P Pregno
- S.C. Ematologia, Dipartimento di Oncologia ed Ematologia, A.O.U. Città della Salute e della Scienza di Torino, Torino, Italy
| | - M Bergamaschi
- Dipartimento di Terapie Oncologiche Integrate, IRCCS AOU S. Martino-IST, Genova, Italy
| | - M Fogli
- Institute of Hematology 'L. & A. Seràgnoli', DIMES, University of Bologna, Bologna, Italy
| | - N Testoni
- Institute of Hematology 'L. & A. Seràgnoli', DIMES, University of Bologna, Bologna, Italy
| | - A De Vivo
- Institute of Hematology 'L. & A. Seràgnoli', DIMES, University of Bologna, Bologna, Italy
| | - F Castagnetti
- Institute of Hematology 'L. & A. Seràgnoli', DIMES, University of Bologna, Bologna, Italy
| | - E Pungolino
- Division of Hematology, Department of Oncology and Hematology, Niguarda Ca' Granda Hospital, Milan, Italy
| | - F Stagno
- Divisione Clinicizzata di Ematologia AOU Policlinico-V. Emanuele, University of Catania, Catania, Italy
| | - M Breccia
- Azienda Policlinico Umberto I, Sapienza Università, Roma, Italy
| | - B Martino
- Hematology Unit, ‘Bianchi-Melacrino-Morelli' Hospital, Reggio Calabria, Italy
| | - T Intermesoli
- Hematology and Bone Marrow Transplant Unit, Azienda Ospedaliera Papa Giovanni XXIII, Bergamo, Italy
| | - G R Cambrin
- University of Turin, San Luigi Gonzaga Hospital, Turin, Italy
| | - G Nicolini
- Hematology and Hematopoietic Stem Cell Transplant Center, San Salvatore Hospital, Pesaro, Italy
| | - E Abruzzese
- Hematology, S Eugenio Hospital Tor Vergata University, Rome, Italy
| | - M Tiribelli
- Division of Hematology and BMT, Azienda Ospedaliero—Universitaria di Udine, Udine, Italy
| | - C Bigazzi
- Hematology, Mazzoni Hospital, Ascoli Piceno, Italy
| | - E Usala
- U O Ematologia e CTMO Ospedale A., Businco-Cagliari, Italy
| | - S Russo
- UOC Ematologia AOU 'G Martino' Policlinico Universitario di Messina, Messina, Italy
| | - A Russo-Rossi
- Division of Hematology, University of Bari, Bari, Italy
| | - M Lunghi
- Division of Hematology, Department of Clinical and Experimental Medicine, Amedeo Avogadro University of Eastern Piedmont, Novara, Italy
| | - M Bocchia
- Hematology and Transplants, University of Siena and AOUS, Siena, Italy
| | - A D'Emilio
- Department of Cellular Therapies and Haematology, San Bortolo Hospital, Vicenza, Italy
| | - V Santini
- Unità di Ematologia, AOU Careggi, University of Florence, Florence, Italy
| | - M Girasoli
- Hematology Department, 'A. Perrino' Hospital, Brindisi, Italy
| | - R Di Lorenzo
- Division of Haematology, Spirito Santo Hospital, Pescara, Italy
| | - S Bernardi
- Unit of Blood Diseases and Stem Cell Transplantation, University of Brescia, Brescia, Italy
| | - A Di Palma
- Unit of Blood Diseases and Stem Cell Transplantation, University of Brescia, Brescia, Italy
| | - B M Cesana
- DMMT, Unit of Medical Statistics, University of Brescia, Brescia, Italy
| | - S Soverini
- Institute of Hematology 'L. & A. Seràgnoli', DIMES, University of Bologna, Bologna, Italy
| | - G Martinelli
- Institute of Hematology 'L. & A. Seràgnoli', DIMES, University of Bologna, Bologna, Italy
| | - G Rosti
- Institute of Hematology 'L. & A. Seràgnoli', DIMES, University of Bologna, Bologna, Italy
| | - M Baccarani
- Department of Haematology-Oncology 'L. and A. Seràgnoli' – S. Orsola Malpighi Hospital, University of Bologna, Bologna, Italy
| |
Collapse
|
6
|
Skert C, Fogli M, Garrafa E, Perucca S, Fiorentini S, Cancelli V, Turra A, Ribolla R, Filì C, Malagola M, Bergonzi C, Cattina F, Bernardi S, Caruso A, Di Palma A, Russo D. A specific Toll-like receptor profile on T lymphocytes and values of monocytes correlate with bacterial, fungal, and cytomegalovirus infections in the early period of allogeneic stem cell transplantation. Transpl Infect Dis 2014; 16:697-712. [DOI: 10.1111/tid.12264] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/02/2014] [Revised: 04/10/2014] [Accepted: 04/21/2014] [Indexed: 01/30/2023]
Affiliation(s)
- C. Skert
- Hematology; Stem Cell Transplantation Unit; University of Brescia; Brescia Italy
| | - M. Fogli
- Section of Microbiology; Department of Experimental and Applied Medicine; University of Brescia; Brescia Italy
| | - E. Garrafa
- Section of Microbiology; Department of Experimental and Applied Medicine; University of Brescia; Brescia Italy
| | - S. Perucca
- Hematology; Stem Cell Transplantation Unit; University of Brescia; Brescia Italy
| | - S. Fiorentini
- Section of Microbiology; Department of Experimental and Applied Medicine; University of Brescia; Brescia Italy
| | - V. Cancelli
- Hematology; Stem Cell Transplantation Unit; University of Brescia; Brescia Italy
| | - A. Turra
- Hematology; Stem Cell Transplantation Unit; University of Brescia; Brescia Italy
| | - R. Ribolla
- Hematology; Stem Cell Transplantation Unit; University of Brescia; Brescia Italy
| | - C. Filì
- Hematology; Stem Cell Transplantation Unit; University of Brescia; Brescia Italy
| | - M. Malagola
- Hematology; Stem Cell Transplantation Unit; University of Brescia; Brescia Italy
| | - C. Bergonzi
- Hematology; Stem Cell Transplantation Unit; University of Brescia; Brescia Italy
| | - F. Cattina
- Hematology; Stem Cell Transplantation Unit; University of Brescia; Brescia Italy
| | - S. Bernardi
- Hematology; Stem Cell Transplantation Unit; University of Brescia; Brescia Italy
| | - A. Caruso
- Section of Microbiology; Department of Experimental and Applied Medicine; University of Brescia; Brescia Italy
| | - A. Di Palma
- Hematology; Stem Cell Transplantation Unit; University of Brescia; Brescia Italy
| | - D. Russo
- Hematology; Stem Cell Transplantation Unit; University of Brescia; Brescia Italy
| |
Collapse
|
7
|
Padovani A, Premi E, Pilotto A, Gazzina S, Cosseddu M, Archetti S, Cancelli V, Paghera B, Borroni B. Overlap between Frontotemporal Dementia and Alzheimer's Disease: Cerebrospinal Fluid Pattern and Neuroimaging Study. ACTA ACUST UNITED AC 2013; 36:49-55. [DOI: 10.3233/jad-121969] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
Affiliation(s)
- Alessandro Padovani
- Centre for Neurodegenerative Disorders, Neurology Unit, University of Brescia, Brescia, Italy
| | - Enrico Premi
- Centre for Neurodegenerative Disorders, Neurology Unit, University of Brescia, Brescia, Italy
| | - Andrea Pilotto
- Centre for Neurodegenerative Disorders, Neurology Unit, University of Brescia, Brescia, Italy
| | - Stefano Gazzina
- Centre for Neurodegenerative Disorders, Neurology Unit, University of Brescia, Brescia, Italy
| | - Maura Cosseddu
- Centre for Neurodegenerative Disorders, Neurology Unit, University of Brescia, Brescia, Italy
| | | | - Vanessa Cancelli
- Centre for Neurodegenerative Disorders, Neurology Unit, University of Brescia, Brescia, Italy
| | - Barbara Paghera
- Department of Nuclear Medicine, University of Brescia, Brescia, Italy
| | - Barbara Borroni
- Centre for Neurodegenerative Disorders, Neurology Unit, University of Brescia, Brescia, Italy
| |
Collapse
|
8
|
Milanesi E, Bonvicini C, Alberici A, Pilotto A, Cattane N, Premi E, Gazzina S, Archetti S, Gasparotti R, Cancelli V, Gennarelli M, Padovani A, Borroni B. Molecular signature of disease onset in granulin mutation carriers: a gene expression analysis study. Neurobiol Aging 2013; 34:1837-45. [PMID: 23419701 DOI: 10.1016/j.neurobiolaging.2012.11.016] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/19/2012] [Revised: 11/09/2012] [Accepted: 11/22/2012] [Indexed: 11/17/2022]
Abstract
Mutations within Granulin (GRN) gene are causative of autosomal dominant frontotemporal lobar degeneration (FTLD). Though GRN mutations are inherited at birth, the disease onset usually occurs in the sixth decade of life. The objective of this study was to identify new genetic pathways linked to inherited GRN disease and involved in the shift from asymptomatic to symptomatic stages. Microarray gene expression analysis on leukocytes was carried out on 15 patients carrying GRN T272SfsX10 mutation, and their asymptomatic siblings with (n = 14) or without (n = 11) GRN mutation. The results were then validated by real-time polymerase chain reaction, and compared with those obtained in a cohort of FTLD without GRN mutation (n = 16). The association between candidate genes and damage of specific brain areas was investigated by voxel-based morphometry on magnetic resonance imaging scans (family-wise error-corrected). Leukocytes mRNA levels of TMEM40 and LY6G6F and other genes mainly involved in inflammation were significantly higher in patients carrying GRN mutations compared with asymptomatic carriers and other FTLD. The higher the levels of TMEM40 the greater is the damage of parietal lobule; the higher the LY6G6F gene expression the greater is the atrophy in superior frontal gyrus. Enhanced inflammation associated with the onset of GRN disease might be either related to disease pathogenetic mechanism leading to neurodegeneration or to a compensatory pathway that counteracts disease progression. The identification of specific molecular targets of GRN-FTLD disease is essential when considering future disease-modifying therapies.
Collapse
Affiliation(s)
- Elena Milanesi
- Department of Biomedical Sciences and Biotechnology, School of Medicine, University of Brescia, Brescia, Italy
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
9
|
Borroni B, Grassi M, Premi E, Alberici A, Cosseddu M, Cancelli V, Caobelli F, Paghera B, Padovani A. Is Long-Term Prognosis of Frontotemporal Lobar Degeneration Predictable by Neuroimaging? Evidence from a Single-Subject Functional Brain Study. ACTA ACUST UNITED AC 2012; 29:883-90. [DOI: 10.3233/jad-2012-112078] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
Affiliation(s)
- Barbara Borroni
- Center for Aging Brain and Dementia, Department of Neurology, University of Brescia, Brescia, Italy
| | - Mario Grassi
- Department of Health Sciences, Section of Medical Statistics and Epidemiology, University of Pavia, Pavia, Italy
| | - Enrico Premi
- Center for Aging Brain and Dementia, Department of Neurology, University of Brescia, Brescia, Italy
| | - Antonella Alberici
- Center for Aging Brain and Dementia, Department of Neurology, University of Brescia, Brescia, Italy
| | - Maura Cosseddu
- Center for Aging Brain and Dementia, Department of Neurology, University of Brescia, Brescia, Italy
| | - Vanessa Cancelli
- Center for Aging Brain and Dementia, Department of Neurology, University of Brescia, Brescia, Italy
| | | | - Barbara Paghera
- Nuclear Medicine Unit, University of Brescia, Brescia, Italy
| | - Alessandro Padovani
- Center for Aging Brain and Dementia, Department of Neurology, University of Brescia, Brescia, Italy
| |
Collapse
|
10
|
Ghiandoni G, Seclì R, Rocchi MB, Ugolini G, Cancelli V. Some unexpected results in time distribution analysis of spontaneous deliveries. Gynecol Obstet Invest 1998; 46:88-90. [PMID: 9701686 DOI: 10.1159/000010008] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
Abstract
OBJECTIVE To study time distribution of spontaneous deliveries. METHODS A retrospective analysis of 1,791 spontaneous deliveries over a 4-year period (1993-1996) was made at the department of Obstetrics and Gynaecology, Civil Hospital, Fano, Italy. Circular statistics techniques (maximization of mean vector length) were used. RESULTS Some unexpected infradian disuniformities (with 60- and 90-hour periods) were observed. Moreover, a correlation between the distribution of spontaneous deliveries and the lunar phases was found. CONCLUSIONS In this study, some unexpected infradian disuniformities were found. However, no biological explanations appear to be reasonable in light of current knowledge, so the interpretation of these results remains an open question.
Collapse
Affiliation(s)
- G Ghiandoni
- Institute of Biomathematics, Urbino University, Urbino, Italy
| | | | | | | | | |
Collapse
|